Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement-Reference-Cited by-同舟云学术

Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement

Published:2017-08-29 Issue:5 Volume:59 Page:1256-1259
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Hiemcke-Jiwa Laura S.¹,Leguit Roos J.¹,Radersma-van Loon Joyce H.¹,Westerweel Peter E.²,Rood Johannes J. M.³,Doorduijn Jeanette K.⁴,Huibers Manon M. H.¹,Minnema Monique C.⁵

Affiliation:

1. Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands;

2. Department of Internal Medicine, Albert Schweitzer hospital Dordrecht, Dordrecht, The Netherlands;

3. Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Faculty of Science, Utrecht, The Netherlands;

4. Department of Hematology, Erasmus Cancer Institute Rotterdam, Rotterdam, The Netherlands;

5. Department of Hematology, University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1369074

Reference14 articles.

1. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia

2. Survival outcomes of secondary cancers in patients with waldenström macroglobulinemia: An analysis of the SEER database

3. MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia